【摘要】 目的 :探讨结直肠癌患者血清血管内皮生长因子 (vascularendothelialgrowthfactor ,VEGF)水平变化的临床意义。方法 :采用双抗夹心ELISA法检测 45例结直肠癌患者血清VEGF水平 ,并与正常人比较。结果 :结直肠癌患者血清VEGF水平 [( 199 47± 15 6 69)pg/mL]显著高于正常对照组 [( 5 1 2 3± 2 2 66)pg/mL] ,P =0 0 0 0 ;有血管侵犯 [( 2 5 1 63±170 19)pg/mL ]、淋巴结转移 [( 2 66 3 9±162 49)pg/mL]和肝脏转移 [( 3 14 48± 2 19 89)pg/mL]的结直肠癌患者血清VEGF水平明显高于无血管侵犯 [( 12 1 2 3± 91 91)pg/mL]、无淋巴结转移 [( 189 2 6± 47 14 )pg/mL]和无肝脏转移 [( 15 7 65± 10 1 86)pg/mL]的患者 ,分别P =0 0 0 5 ,P =0 0 0 0 ,P =0 0 0 2 ;Duke’sC、D期的结直肠癌患者血清VEGF水平 [( 2 60 74±174 72 )pg/mL]显著高于Duke’sA、B期患者[( 115 63± 69 10 )pg/mL] ,P =0 0 0 1;结直肠肿瘤≥ 5cm的患者血清VEGF水平 [( 2 44 74±171 18)pg/mL]明显高于肿瘤 <5cm的患者[( 12 4 92± 92 62 )pg/mL] ,P =0 0 0 4。血清VEGF水平与患者性别、年龄和组织病理学类型无明显关系。结论 :血清VEGF有可能成为一个新的肿瘤标志物而用于结直肠癌诊断、病情进展的动态监测及预后判断的更多还原

【Abstract】 OBJECTIVE:To explore the clinical significance of serum vascular endothelial growth factor (VEGF) level change in patients with colorectal cancer.METHODS:Serum VEGF levels of 45 patients with colorectal cancer were measured by sandwich enzym-linked immunosorbent assay (ELISA).Forty normal healthy volunteers served as control.RESULTS:The serum VEGF level of patients with colorectal cancer [(199.47±156.69) pg/mL] was significantly higher than that of the control group[(51.23±22.66) pg/mL],P=0.000. The serum VEGF level in colorectal cancer patients with vascular invasion[(251.63±170.19) pg/mL],lymph node metastasis[(266.39±162.49) pg/mL], liver metastasis [(314.48±219.89) pg/mL] and tumor size ≥5.0 cm [(244.74±171.18) pg/mL] was significantly higher than that in colorectal carcinoma patients without vascular invasion[(121.23±91.91) pg/mL], lymph node metastasis [(189.26±47.14) pg/mL], liver metastasis [(157.65±101.86) pg/mL] and tumor size <5.0 cm [(124.92±92.62) pg/mL],P=0.005,P =0.000,P=0.002, P= 0.004 respectively. The serum VEGF level in colorectal cancer patients of Dukes C and D stage [(260.74±174.72) pg/mL] was significantly higher than that in colorectal cancer patients of Dukes A and B stage [(115.63±69.10) pg/mL],P =0.001.There was no significant difference of the serum VEGF level in colorectal cancer patient’s gander,age and pathological types.CONCLUSION:Serum VEGF may be used as a new tumor marker of colorectal cancer,for diagnosis and monitoring the progress of the disease.更多还原